Table 2.

Summary of lymphocyte transformation test (LTT) results for Patient 1 and Patient 2.

			COVID-19 vaccine						Vaccine components
			ChAdOx1		BNT162b2		NVX-CoV2373		Polysorbate 80		PEG 2050
			ANOVA	SI	ANOVA	SI	ANOVA	SI	ANOVA	SI	ANOVA	SI
Patient 1	LTT	Dilution 1	***	5.4	NS	1.5			**	4.0	NS	1.0
		Dilution 2	****	6.3	NS	1.5			****	5.9	NS	2.7
		Dilution 3	****	6.3	NS	1.6			NS	2.8	NS	2.6
		Dilution 4	***	6.2	NS	1.5			NS	2.2	NS	1.8
		Dilution 5	NS	5.3	NS	1.3			NS	1.5	NS	1.7
		Dilution 6	NS	3.5	NS	2			NS	1.2	NS	0.3
		CD3/CD28	****	8.7
		PHA	****	7.8
Patient 2	First LTT	Dilution 1	NS	0.5	NS	1.1			NS	0	NS	1.2
		Dilution 2	NS	0.6	**	2.0			NS	0.9	NS	1.2
		Dilution 3	NS	0.7	NS	1.1			NS	1.5	NS	1.1
		Dilution 4	NS	1.1	NS	1.0			NS	1.5	NS	1.1
		Dilution 5	NS	0.9	NS	1.2			NS	1.1	NS	0.8
		Dilution 6	NS	0.9	NS	1.0			NS	1.1	NS	1.1
		CD3/CD28	NNS	1.16
		PHA	NNS	1.32
	Post infection	Dilution 1	NS	1.83	NS (AD)	<2 (AD)	***	11.1	NS (AD)	<2 (AD)	NS (AD)	<2 (AD)
		Dilution 2	**	2.2			****	19.8
		Dilution 3	**	2.2			****	12.8
		Dilution 4	**	2.2			**	9.3
		Dilution 5	*	2.1			*	7.68
		Dilution 6	**	2.5			NS	2.8
		CD3/CD28	****	4.1
		PHA	****	3.2

NS = Not significant, ANOVA *p < .05, **p < .01 and ***p < .001 ****p < .0001.

SI greater > 2 Positive. (AD) = All dilutions.